Clinical Trial Update: Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study evaluating alirocumab (SAR236553/REGN727) given subcutaneously at three different injection sites in healthy subjects to assess …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 1 | Status: COMPLETED